Bottom line
Is FBDIX a good fund? The bottom line
FBDIX is the Class A share class of Franklin Biotechnology Discovery Fund, an actively managed technology sector mutual fund from Franklin Templeton.
Its expense ratio is 1.01% — about $101 a year on every $10,000 invested, more expensive than 71% of technology sector funds we track.
It returned +43.9% over one year, +5.0% a year over five years, +6.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.2 billion in net assets and 126 holdings, its largest position is Jazz Pharmaceuticals plc (5.7%) and the top 10 make up 36.3% of the portfolio.
This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.01%)
- Front-end sales load up to 5.5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What FBDIX invests in
Capital appreciation.
"Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Funds investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the companys most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such…
From the fund's prospectus (filed Aug 25, 2026).
FBDIX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FBDIX | +43.9% | +5.0% | +6.4% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What FBDIX costs
On a $10,000 investment, FBDIX's 1.01% expense ratio costs about $101 a year. The prospectus estimates $1,728 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
FBDIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Jazz Pharmaceuticals plc | 5.66% |
| 2 | Amgen, Inc. | 4.39% |
| 3 | Gilead Sciences, Inc. | 3.86% |
| 4 | Regeneron Pharmaceuticals, Inc. | 3.77% |
| 5 | Argenx SE | 3.62% |
| 6 | Vertex Pharmaceuticals, Inc. | 3.54% |
| 7 | Franklin Institutional U.S. Government Money Market Fund | 3.18% |
| 8 | Revolution Medicines, Inc. | 3.01% |
| 9 | Guardant Health, Inc. | 2.76% |
| 10 | Ascendis Pharma A/S | 2.56% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 36.3% of the fund. See all top 25 holdings and asset mix →